信立泰: 2025年半年度报告摘要

Core Viewpoint - Shenzhen Salubris Pharmaceuticals Co., Ltd. reported a revenue increase of 4.32% year-on-year for the first half of 2025, indicating stable growth in its operations [1][2]. Financial Performance - The company's operating income for the reporting period was approximately CNY 2.13 billion, compared to CNY 2.04 billion in the same period last year, reflecting a growth of 4.32% [1]. - The net profit attributable to shareholders was approximately CNY 365.08 million, up 6.10% from CNY 344.09 million in the previous year [1]. - The net cash flow from operating activities decreased by 20.19%, amounting to approximately CNY 425.43 million, down from CNY 533.06 million [1]. - Basic and diluted earnings per share increased by 6.45% to CNY 0.33 [1]. - The weighted average return on equity slightly decreased to 4.19%, down from 4.29% [1]. Asset and Equity Position - Total assets at the end of the reporting period were approximately CNY 10.63 billion, an increase from CNY 10.47 billion at the end of the previous year [1]. - The net assets attributable to shareholders decreased by 1.99% to approximately CNY 8.54 billion [2]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,019 [2]. - The largest shareholder, Salubris Pharmaceuticals Co., Ltd., holds 56.99% of the shares [2][3]. - There were no changes in the controlling shareholder or actual controller during the reporting period [3].